NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — AMC Global Media Inc. (“AMC Global Media” or the “Company”) (NASDAQ: AMCX) today reported financial results for the second quarter ended June 30, 2026. Chief Executive Officer Kristin Dolan said: “We are pleased to announce today an expansion of our relationship with a key long-term partner, Netflix. We have reached a global co-exclusive licensing agreement for the streaming rights to the entire Walking Dead Universe, which will provide a meaningful source of cash flow for years to come. We renewed distribution agreements with major partners Comcast and YouTube. We are increasing our guidance for the full year as we leverage the value of our IP, the importance of our studio and the strength of our partner relationships, particularly in the area of distribution.” Operational...

ANTIOCH, Tenn., July 30, 2026 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today reported second quarter 2026 financial results and provided an updated outlook for 2026. “Our second‑quarter performance reflected solid execution across our North America and Specialty segments. North America returned to positive organic growth for the first time in nine quarters, driven by record alternative-parts utilization of over 40%, moderating insurance premiums that were negative in May and June, and continued sequential improvement in repairable claims. Specialty also delivered growth despite a challenging end‑market environment and continued macro‑economic pressure on consumers. Europe fell short of expectations, with results affected by the ERP implementation in Germany. Outside of the ERP impact, the team delivered substantial...

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 reflecting continued strong physician adoption and high patient demand Strengthened IP portfolio with 3 new resmetirom patents, including F4c patent MGL-2086 (oral GLP-1) Phase 1 trial dosing initiated in June 2026 as part of Rezdiffra/MGL-2086 combination program in MASH Reports cash, cash equivalents, restricted cash and marketable securities of $838.9 million as of June 30, 2026 Company to host conference call today, July 30, 2026, at 8 a.m. EDTCONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...

NEWPORT NEWS, Va., July 30, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) today reported results for the second quarter of fiscal 2026. HighlightsSecond quarter revenues were $3.4 billion Second quarter net earnings were $208 million or $5.27 diluted earnings per share Company raises the FY26 shipbuilding revenue guidance range to between $10.2 and $10.4 billion1 Company raises the low end of the FY26 shipbuilding operating margin2 guidance range1 Company reaffirms previously issued free cash flow2 outlook1Second Quarter ResultsSecond quarter 2026 revenues of $3.4 billion were up 10.9% from the second quarter of 2025, driven by growth at Newport News Shipbuilding and Ingalls Shipbuilding. Operating income in the second quarter of 2026 was $210 million and operating margin was 6.1%, compared to $163 million and 5.3%, respectively,...

— China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each — — FRUZAQLA® ex-US sales driving growth – now approved or launched in 41 countries — — Strong progress in ATTCs, a source of novel drug candidates with broad therapeutic potential — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 2026 and provides updates on key clinical and commercial developments. All amounts are expressed in US dollars unless otherwise stated. A glossary of abbreviations is on page 25. Global sales growth driven by China rebound and FRUZAQLA® geographical expansionIn-market sales from key China commercial products up over 40%...

Double-digit revenue growth across all three platforms; 2026 outlook reaffirmed Second quarter operating highlights:     Three months ended   Six months ended    June 30   June 30(in millions of US$, except EPS)   2026     2025     2026     2025                         Revenues $ 1,572.5   $ 1,347.6   $ 2,886.0   $ 2,488.8Net Revenues (note 1)   1,386.3     1,185.9     2,536.4     2,179.6Adjusted EBITDA (note 2)   205.3     180.2     330.1     296.3Adjusted EPS (note 3)   1.83     1.72     2.74     2.59                         GAAP operating earnings   98.4     99.2     133.4     130.8GAAP diluted net earnings per share   0.56     0.08     0.09     0.00    TORONTO, July 30, 2026 (GLOBE NEWSWIRE) — Colliers...

First Quarter Sales Increased by 27% Year-over-Year to $259 Million MANCHESTER, N.H., July 30, 2026 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its first quarter ended June 26, 2026. “We began fiscal 2027 with strong momentum, delivering our sixth consecutive quarter of sales growth. Fiscal first quarter sales were $259 million, representing a 27% increase year-over-year. GAAP earnings per share improved to $0.08 in fiscal first quarter 2027 from a $0.07 loss per share in fiscal first quarter 2026. Non-GAAP EPS grew for the fifth consecutive quarter to $0.23, increasing more than 2.5x over the first quarter of fiscal 2026. These results...

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss its financial results and provide a business and portfolio update. Audio WebcastThe call will be webcast live and can be accessed by visiting...

The Company once again delivered record quarterly net gaming revenue of €69.4 million and Adj. EBITDA of €5.8 millionTotal revenue was €64.4 mm in Q2 2026, while net gaming revenue1 was €69.4 mm, 27% above Q2 2025. Spain revenue and net gaming revenue were €27.6 mm in Q2 2026, 25% above Q2 2025. Mexico revenue was €31.8 mm in Q2 2026, while net gaming revenue was €36.1 mm, 24% above Q2 2025. Adj. EBITDA reached €5.8 mm in Q2 2026, €3.5 mm above Q2 2025. Net income was €5.6 mm in H1 2026 versus a net loss of €3.1 mm in H1 2025. Total cash position of €62.6 mm and no financial debt as of June 30, 2026. Increasing FY 2026 outlook of net gaming revenue to €255-265 mm and Adj. EBITDA2 to €20-25 mm.Madrid, Spain and Tel Aviv, Israel, July 30, 2026 – (GLOBE NEWSWIRE) Codere Online (Nasdaq: CDRO / CDROW, the “Company”), a leading online...

CHICAGO, July 30, 2026 (GLOBE NEWSWIRE) — CCC Intelligent Solutions Holdings Inc. (“CCC” or the “Company”) (NASDAQ: CCC), a leading SaaS and AI platform provider for the multi-trillion-dollar insurance economy, today announced its financial results for the three months ended June 30, 2026.  “CCC delivered another quarter of solid execution, with second quarter revenue growth of 10% and adjusted EBITDA margin of approximately 40%. Our performance reinforces our vision for CCC to be the connective layer for the insurance economy – a network that helps every participant act, not just record,” said Githesh Ramamurthy, Chairman & CEO of CCC. “We continue to see customers deploy AI operationally and at scale to solve real business problems. As adoption expands across our platform, it reinforces the value of our data, workflows,...